RGS16, a novel p53 and prb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells

Genes and Cancer

Volumn 5, Issue 11-12, 2014, Pages 420-435

  Carper, Miranda B ^a   Denvir, James ^a   Boskovic, Goran ^a   Primerano, Donald A ^a   Claudio, Pier Paolo ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGF; Migration; P53; Pancreatic cancer; PRb; RGS16

Indexed keywords

ADENOVIRUS VECTOR; BCL2L11 PROTEIN; BTG 2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; PROTEIN P53; RETINOBLASTOMA PROTEIN; STAT4 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA MICROARRAY; DOWN REGULATION; FLUORESCENCE MICROSCOPY; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; PANCREAS CANCER; PANCREAS METASTASIS; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATOR OF G PROTEIN SIGNALING 16 GENE; SAOS 2 CELL LINE; TUMOR DIFFERENTIATION; UPREGULATION; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM;

EID: 84949508564     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Cordon-Cardo, C., et al., Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res, 1997. 57(7): p. 1217-21.
2. Friend, S.H., et al., A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature, 1986. 323(6089): p. 643-6.
3. Toguchida, J. and T. Nakayama, Molecular genetics of sarcomas: applications to diagnoses and therapy. Cancer Sci, 2009. 100(9): p. 1573-80.
4. Williams, B.O., et al., Tumorigenic and developmental effects of combined germ-line mutations in Rb and p53. Cold Spring Harb Symp Quant Biol, 1994. 59: p. 449-57.
5. Mathew, R., et al., Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur J Cancer, 2002. 38(6): p. 832-41.
6. Barton, C.M., et al., Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer, 1991. 64(6): p. 1076-82.
7. Caldas, C., et al., Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet, 1994. 8(1): p. 27-32.
8. Laurie, N.A., et al., Inactivation of the p53 pathway in retinoblastoma. Nature, 2006. 444(7115): p. 61-6.
9. Yap D.B., et al., mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene, 1999. 18(53): p. 7681-9.
10. Dong, Y., et al., Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer, 1997. 74(4): p. 407-15.
11. Zhou, Z., et al., Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res, 2006. 66(16): p. 7889-98.
12. Yin, Y., et al., Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress. Mol Carcinog, 1999. 24(1): p. 15-24.
13. Sherr, C.J. and F. McCormick, The RB and p53 pathways in cancer. Cancer Cell, 2002. 2(2): p. 103-12.
14. Polager, S. and D. Ginsberg, p53 and E2f: partners in life and death. Nat Rev Cancer, 2009. 9(10): p. 738-48.
15. Buckbinder, L., et al., The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc Natl Acad Sci U S A, 1997. 94(15): p. 7868-72.
16. De Vries, L., et al., The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol, 2000. 40: p. 235-71.
17. Berthebaud, M., et al., RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood, 2005. 106(9): p. 2962-8.
18. Johnson, E.N., et al., RGS16 inhibits signalling through the G alpha 13-Rho axis. Nat Cell Biol, 2003. 5(12): p. 1095-103.
19. Liang, G., et al., RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3- kinase signaling. J Biol Chem, 2009. 284(32): p. 21719-27.
20. Teicher, B.A. and S.P. Fricker, CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res, 2010. 16(11): p. 2927-31.
21. Marchesi, F., et al., Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res, 2004. 64(22): p. 8420-7.
22. Ng, S.S.W., et al., Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res, 2000. 60(19): p. 5451-5.
23. Schlieman, M.G., et al., Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer, 2003. 89(11): p. 2110-5.
24. Osaki, M., M. Oshimura, and H. Ito, PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis, 2004. 9(6): p. 667-76.
25. Wiechec, E., J. Overgaard, and L.L. Hansen, A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. Genes Chromosomes Cancer, 2008. 47(9): p. 766-80.
26. Kim, J.H., et al., RGS16 and FosB underexpressed in pancreatic cancer with lymph node metastasis promote tumor progression. Tumour Biol, 2010. 31(5): p. 541-8.
27. Mian, O.Y., et al., Management options in locally advanced pancreatic cancer. Curr Oncol Rep, 2014. 16(6): p. 388.
28. Hidalgo, M., Pancreatic cancer. N Engl J Med, 2010. 362(17): p. 1605-17.
29. Ghaneh, P., E. Costello, and J.P. Neoptolemos, Biology and management of pancreatic cancer. Postgrad Med J, 2008. 84(995): p. 478-97.
30. Itahana, K., et al., A role for p53 in maintaining and establishing the quiescence growth arrest in human cells. J Biol Chem, 2002. 277(20): p. 18206-14.
31. Marchesini, N., et al., Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J Biol Chem, 2004. 279(24): p. 25101-11.
32. Zhao, S., et al., Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer, 2010. 127(9): p. 2076-87.
33. Yamanaka, Y., et al., Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res, 1993. 13(3): p. 565-9.
34. Ardito, C.M., et al., EGF receptor is required for KRASinduced pancreatic tumorigenesis. Cancer Cell, 2012. 22(3): p. 304-17.
35. Shinohara, H., et al., Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis. Br J Cancer, 2000. 83(8): p. 1039-46.
36. Ip S.M., et al., pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell lines. Eur J Cancer, 2001. 37(18): p. 2475-83.
37. Derenzini, M., et al., The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein. J Pathol, 2009. 219(3): p. 373-82.
38. Spurgers, K.B., et al., Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem, 2006. 281(35): p. 25134-42.
39. Ho, J. and S. Benchimol, Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ, 2003. 10(4): p. 404-8.
40. Zhao, R., et al., Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev, 2000. 14(8): p. 981-93.
41. Hammond, E.M., et al., Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol, 2006. 26(9): p. 3492-504.
42. Kannan, K., et al., DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene, 2001. 20(18): p. 2225-34.
43. Chen, Y., D. Schlessinger, and R. Nagaraja, T antigen transformation reveals Tp53/RB-dependent route to PLAC1 transcription activation in primary fibroblasts. Oncogenesis, 2013. 2: p. e67.
44. Chen, H.Z., S.Y. Tsai, and G. Leone, Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer, 2009. 9(11): p. 785-97.
45. Claudio, P.P., T. Tonini, and A. Giordano, The retinoblastoma family: twins or distant cousins? Genome Biol, 2002. 3(9): p. reviews 3012.
46. Genovese, C., et al., Cell cycle control and beyond: emerging roles for the retinoblastoma gene family. Oncogene, 2006. 25(38): p. 5201-9.
47. Sun, H., et al., E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. Proc Natl Acad Sci U S A, 2011. 108(2): p. 704-9.
48. Sellers, W.R., et al., Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev, 1998. 12(1): p. 95-106.
49. Batsche, E., et al., Rb enhances p160/SRC coactivatordependent activity of nuclear receptors and hormone responsiveness. J Biol Chem, 2005. 280(20): p. 19746-56.
50. Osada, M., et al., A p53-type response element in the GDF15 promoter confers high specificity for p53 activation. Biochem Biophys Res Commun, 2007. 354(4): p. 913-8.
51. Rouault, J.P., et al., Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet, 1996. 14(4): p. 482-6.
52. Taira, N., et al., Induction of amphiregulin by p53 promotes apoptosis via control of microRNA biogenesis in response to DNA damage. Proc Natl Acad Sci U S A, 2014. 111(2): p. 717-22.
53. Yoon, H., et al., Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15632-7.
54. Hoeferlin, L.A., et al., Folate stress induces apoptosis via p53-dependent de novo ceramide synthe sis and upregulation of ceramide synthase 6. J Biol Chem, 2013. 288(18): p. 12880-90.
55. Jeong, B.S., et al., Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J, 2010. 24(5): p. 1347-53.
56. Sheikh, M.S., et al., The antiapoptotic decoy receptor TRID/ TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene, 1999. 18(28): p. 4153-9.
57. Ohashi, T., et al., AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol Cancer Res, 2013. 11(12): p. 1554-63.
58. Kudoh, T., et al., D4S234E, a novel p53-responsive gene, induces apoptosis in response to DNA damage. Exp Cell Res, 2010. 316(17): p. 2849-58.
59. Jiang H., et al., pRB and p107 have distinct effects when expressed in pRB-deficient tumor cells at physiologically relevant levels. Oncogene, 2000. 19(34): p. 3878-87.
60. Vernell, R., K. Helin, and H. Muller, Identification of target genes of the p16INK4A-pRB-E2F pathway. J Biol Chem, 2003. 278(46): p. 46124-37.
61. Bourgo, R.J., et al., RB restricts DNA damage-initiated tumorigenesis through an LXCXE- dependent mechanism of transcriptional control. Mol Cell, 2011. 43(4): p. 663-72.
62. Daoud, S.S., et al., Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res, 2003. 63(11): p. 2782-93.
63. Dorsam, R.T. and J.S. Gutkind, G-protein-coupled receptors and cancer. Nat Rev Cancer, 2007. 7(2): p. 79-94.
64. Jang, S. and M.B. Atkins, Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther, 2014. 95(1): p. 24-31.
65. Davidsson, J., et al., Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum Mol Genet, 2007. 16(18): p. 2215-25.
66. Miyoshi, N., et al., RGS16 is a marker for prognosis in colorectal cancer. Ann Surg Oncol, 2009. 16(12): p. 3507-14.
67. Liu, T., et al., The retinoid anticancer signal: mechanisms of target gene regulation. Br J Cancer, 2005. 93(3): p. 310-8.
68. Vasilatos, S.N., et al., Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis, 2013. 34(6): p. 1196-207.
69. Lippert, E., et al., Role of regulator of G protein signaling 16 in inflammation-induced T lymphocyte migration and activation. J Immunol, 2003. 171(3): p. 1542-55.
70. Shankar, S.P., et al., RGS16 attenuates pulmonary Th2/Th17 inflammatory responses. J Immunol, 2012. 188(12): p. 6347-56.
71. Kusama, T., et al., Inhibition of epidermal growth factorinduced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutarylcoenzyme a reductase inhibitors. Cancer Res, 2001. 61(12): p. 4885-91.
72. Roger, L., G. Gadea, and P. Roux, Control of cell migration: a tumour suppressor function for p53? Biol Cell, 2006. 98(3): p. 141-52.
73. Liu, J., et al., Wild-type p53 inhibits nuclear factor-kappaBinduced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res, 2006. 4(11): p. 803-10.
74. Sun, Y., et al., Human metalloproteinase-1 (collagenase-1) is a tumor suppressor protein p53 target gene. Ann N Y Acad Sci, 1999. 878: p. 638-41.
75. Sun Y., et al., p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem, 1999. 274(17): p. 11535-40.
76. Zhu, H., et al., A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells. Cancer Biol Ther, 2009. 8(18): p. 1722-8.
77. Andrusiak, M.G., et al., Rb/E2F regulates expression of neogenin during neuronal migration. Mol Cell Biol, 2011. 31(2): p. 238-47.
78. Kim, K.J., et al., Rb suppresses collective invasion, circulation and metastasis of breast cancer cells in CD44-dependent manner. PLoS One, 2013. 8(12): p. e80590.
79. Johnson, J.L., et al., Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res, 2012. 72(2): p. 516-26.
80. Sethakorn, N., D.M. Yau, and N.O. Dulin, Non-canonical functions of RGS proteins. Cell Signal, 2010. 22(9): p. 1274-81.
81. Su, Z.Z., et al., The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci U S A, 1998. 95(24): p. 14400-5.
82. Greco, A., et al., Eradication of therapy-resistant human prostate tumors using an ultrasound- guided site-specific cancer terminator virus delivery approach. Mol Ther, 2010. 18(2): p. 295-306.
83. Nande, R., et al., Targeting a newly established spontaneous feline fibrosarcoma cell line by gene transfer. PLoS One, 2012. 7(5): p. e37743.
84. Tusher, V.G., R. Tibshirani, and G. Chu, Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A, 2001. 98(9): p. 5116-21.
85. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 402-8.
86. Lo, H.W., et al., Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up- regulation of TWIST gene expression. Cancer Res, 2007. 67(19): p. 9066-76.
87. Dittmar, T., et al., Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J, 2002. 16(13): p. 1823-5.
88. Giehl, K., et al., Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene, 2000. 19(25): p. 2930-42.
89. Deer, E.L., et al., Phenotype and genotype of pancreatic cancer cell lines. Pancreas, 2010. 39(4): p. 425-35.
90. Ali, S., et al., Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther, 2005. 4(12): p. 1943-51.